-
CSR Summary Not Yet Available
-
NCT02034162
-
Primary Citation
-
Data Specification Not Available
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameMebendazoleProduct NameVERMOXTherapeutic AreaParasitic DiseasesEnrollment295% Female51.5%% WhiteN/A
Product ClassAntiparasiticsSponsor Protocol NumberMEBENDAZOLGAI3003Data PartnerJohnson & JohnsonCondition StudiedHelminth InfectionsMean/Median Age (Years)7.8
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Clinical Study Report Available